Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Essential nutrient in eggs may reduce risk of infant heart defects

A study published in the American Journal of Clinical Nutrition found that a choline-deficient diet is associated with increased risk for heart defects during prenatal development. Choline is an essential nutrient required for normal cell activity, healthy brain and nerve function, liver metabolism and transportation of nutrients throughout the body.

16 Jul 2010

High blood pressure, diabetes leads to CKD

People with diabetes and high blood pressure need to take care of their kidneys. According to the July issue of Mayo Clinic Women's HealthSource, chronic kidney disease (CKD) is a growing problem in the United States. The most common causes are diabetes and high blood pressure

16 Jul 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Immune system cells called macrophages spring into action to surround and destroy threats such as viruses or cancer cells. But sometimes the would-be protective response leads to persistent inflammation, which, in turn, can cause disease.Scientists don't know exactly how macrophages cross the line from being good cops to bad cops, but researchers at the University of Florida recently unearthed several clues about the mechanisms involved. Through the lens of two inflammation-related diseases, HIV and rheumatoid arthritis, they identified changes in specific proteins linked to the action of macrophages, white blood cells that are key to the body's natural defenses.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Sepracor to change name to Sunovion Pharmaceuticals

Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd., an Osaka, Japan-based pharmaceutical company, announced today the intent to change the Sepracor name to Sunovion Pharmaceuticals Inc. in the United States. DSP acquired Sepracor in October 2009 and the name change is planned to occur in anticipation of the one-year anniversary of the acquisition. Sepracor intends to begin officially operating as Sunovion Pharmaceuticals Inc. before the end of 2010.

15 Jul 2010

St. Luke's Episcopal Hospital ranked among America's elite healthcare institutions

In its annual survey of "America's Best Hospitals," U.S. News & World Report has ranked St. Luke's Episcopal Hospital (SLEH) among the elite healthcare institutions in the nation in five major areas of care. This includes the Texas Heart® Institute (THI) at St. Luke's Episcopal Hospital, listed in the top ten nationally in heart and heart surgery for the 20th consecutive year.

15 Jul 2010

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

After two days of hearings, an advisory committee to the U.S. Food and Drug Administration (FDA) recommended that the FDA allow the type 2 diabetes drug rosiglitazone (brand name, Avandia), to stay on the market, but with most committee members suggesting that the label be revised to include increased warnings. Rosiglitazone is one in a class of drugs called thiazolidinediones (TZDs), used to treat type 2 diabetes.

15 Jul 2010

NIH awards $38.2M grant to Georgetown-Howard Universities Center for Clinical and Translational Science

In support of a critical partnership between Georgetown University Medical Center and Howard University, the National Institutes of Health (NIH) has awarded a $38.2 million Clinical and Translational Sciences Award to aid the universities' effort to transform health care and preventive practices in communities through medical discoveries made in laboratories and clinical settings.

15 Jul 2010

OraVerse MAA accepted for review in five key European countries

Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.

14 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

Research provides better understanding of drugs used to treat, prevent cardiovascular disease

Using chemical labeling and mass spectrometry-based techniques, Mark Chance, PhD, director of the Case Western Reserve University School of Medicine Center for Proteomics and Bioinformatics and professor of physiology and biophysics; Sayan Gupta, PhD, instructor at the Case Center for Proteomics and Bioinformatics; and a research team from the University of Oxford, for the first time, were able to take a high resolution picture of the open state of a K+ channel, allowing them to comparatively analyze gating mechanisms important to heart function and nerve signaling - in addition these techniques have already permitted Case Western investigators to gain a deeper understanding of G-protein coupled receptors.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Commercial cholesterol measurement techniques produce mixed results: Study

The National Cholesterol Education Program maintains guidelines to assess the accuracy of methods for measuring cholesterol levels in patients. A recent study published in the journal Clinical Chemistry found that seven leading commercial methods produce results of mixed accuracy when compared to well-established techniques.

14 Jul 2010

IAS announces recipients of CNIHR grants

The International AIDS Society today announced the recipients of its first joint research grant programme, Creative and Novel Ideas in HIV Research. CNIHR grants, funded in partnership with the U.S. National Institutes of Health and the NIH-supported Centers for AIDS Research are designed to promote innovative research and new ideas from early stage investigators whose primary focus has previously been in fields of scientific inquiry other than HIV/ AIDS.

14 Jul 2010

Exposure to cigarette smoke can alter gene expression, study finds

In the largest study of its kind, researchers at the Southwest Foundation for Biomedical Research have found that exposure to cigarette smoke can alter gene expression -- the process by which a gene's information is converted into the structures and functions of a cell. These alterations in response to smoking appear to have a wide-ranging negative influence on the immune system, and a strong involvement in processes related to cancer, cell death and metabolism.

14 Jul 2010

Individual genes and networks that play an important role in inflammation, atherosclerosis identified

HemoShear, LLC, a leading developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds, has produced a profile of all of the genes that influence the biology and function of the human artery system. This research has generated valuable information on the entire spectrum of genes that are found in specific cell-types that make up human arteries.

14 Jul 2010

Amira granted UK patents for AM103, AM803 FLAP inhibitors for respiratory disorders

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.

14 Jul 2010

Combined behavioral interventions most effective way to reduce heart disease risk

Combining counseling, extended follow-up with a healthcare provider and self-monitoring of diet and exercise is the most effective way to help patients embrace lifestyle changes that can lower their risk for heart and blood vessel (cardiovascular) diseases, according to a scientific statement published in Circulation: Journal of the American Heart Association.

13 Jul 2010

BioImage Study published in American Heart Journal

BG Medicine, Inc., a U.S.-based biomarker discovery and in vitro diagnostics company, announced today the publication of The BioImage Study trial design and key objectives in the American Heart Journal. The American Heart Journal is a peer- reviewed journal that publishes original research and review articles on clinical research studies in the field of cardiology.

13 Jul 2010

Women with gestational diabetes during first, second pregnancies at increased risk of recurrence

There is an increased risk of recurring gestational diabetes in pregnant women who developed gestational diabetes during their first and second pregnancies, according to a Kaiser Permanente study appearing online in The American Journal of Obstetrics and Gynecology.

13 Jul 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Essential nutrient in eggs may reduce risk of infant heart defects

High blood pressure, diabetes leads to CKD

New findings on macrophage activation can facilitate development of early diagnosis tools

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Sepracor to change name to Sunovion Pharmaceuticals

St. Luke's Episcopal Hospital ranked among America's elite healthcare institutions

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

NIH awards $38.2M grant to Georgetown-Howard Universities Center for Clinical and Translational Science

OraVerse MAA accepted for review in five key European countries

Trevena completes $35M Series B financing

Research provides better understanding of drugs used to treat, prevent cardiovascular disease

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Commercial cholesterol measurement techniques produce mixed results: Study

IAS announces recipients of CNIHR grants

Exposure to cigarette smoke can alter gene expression, study finds

Individual genes and networks that play an important role in inflammation, atherosclerosis identified

Amira granted UK patents for AM103, AM803 FLAP inhibitors for respiratory disorders

Combined behavioral interventions most effective way to reduce heart disease risk

BioImage Study published in American Heart Journal

Women with gestational diabetes during first, second pregnancies at increased risk of recurrence

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Newsletters you may be interested in